Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Pulse Biosciences (PLSE) experienced a 29% increase in trading volume, with approximately 229,365 shares traded on Friday, while its stock price rose from $18.99 to $20.11.
• The company reported a loss of ($0.28) earnings per share for its last quarterly earnings, which was below the consensus estimate of ($0.26).
• Research analysts have mixed ratings on Pulse Biosciences, with one "Buy" and one "Sell" rating, resulting in a consensus rating of "Hold" and a price target of $22.00.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) saw unusually-high trading volume on Friday . Approximately 229,365 shares were traded during mid-day trading, an increase of 29% from the previous session's volume of 177,694 shares.The stock last traded at $20.11 and had previously closed at $18.99.

Analyst Ratings Changes

PLSE has been the subject of a number of research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a report on Saturday, September 27th. Oppenheimer started coverage on Pulse Biosciences in a research report on Monday, July 7th. They issued an "outperform" rating and a $22.00 target price for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $22.00.

Pulse Biosciences Stock Up 1.6%

The stock's 50 day moving average price is $16.02 and its 200-day moving average price is $16.20. The stock has a market capitalization of $1.30 billion, a PE ratio of -18.37 and a beta of 1.79.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Insider Buying and Selling

In other news, insider Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $18.49, for a total transaction of $369,800.00. Following the completion of the sale, the insider owned 43,298 shares of the company's stock, valued at approximately $800,580.02. The trade was a 31.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert W. Duggan bought 34,659 shares of the stock in a transaction on Wednesday, September 10th. The stock was purchased at an average price of $14.66 per share, with a total value of $508,100.94. Following the completion of the acquisition, the director directly owned 47,551,200 shares in the company, valued at approximately $697,100,592. This trade represents a 0.07% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 90,400 shares of company stock worth $1,465,142 over the last three months. 74.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Pulse Biosciences by 14.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,308 shares of the company's stock worth $667,000 after purchasing an additional 4,773 shares during the last quarter. GAMMA Investing LLC grew its stake in Pulse Biosciences by 2,203.1% during the 1st quarter. GAMMA Investing LLC now owns 6,034 shares of the company's stock worth $97,000 after buying an additional 5,772 shares during the last quarter. Rhumbline Advisers increased its position in Pulse Biosciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock valued at $440,000 after buying an additional 1,614 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Pulse Biosciences by 24.6% in the first quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after buying an additional 1,778 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its holdings in Pulse Biosciences by 5.5% in the first quarter. Westside Investment Management Inc. now owns 58,155 shares of the company's stock worth $936,000 after acquiring an additional 3,034 shares in the last quarter. Institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.